Typically, tumor-associated Tregs occupy approximately 10%–50% of CD4+ T cells in tumors, which is profoundly greater than that residing in the peripheral blood of healthy individuals (2%–5%) [535, 536]. The gene discussed is CD4; the disease is neoplasm.